This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Rheumatology  • Rheumatoid Arthritis  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic

Martin Stichenwirth, MD; Elisabeth Riedl, MD; Hubert Pehamberger, MD; Gerhard Tappeiner, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Adalimumab is a recombinant human IgG1 monoclonal antibody specific for tumor necrosis factor (TNF-). Pharmacologic blockade of TNF- has proven beneficial in a variety of chronic inflammatory conditions, including rheumatoid arthritis and psoriasis.¹ It has also been successfully used in the treatment of pyoderma gangrenosum,² a noninfectious skin disorder frequently associated with rheumatoid arthritis, ulcerative colitis, or hematologic malignancy. A growing number of adverse skin reactions to anti–TNF- agents, including local reactions at the injection site, nonspecific rashes, isolated cases of bullous skin lesions, leukocytoclastic vasculitis,³ and erythema multiforme,⁴ have been reported. Moreover, development of psoriasis⁵ during anti–TNF- treatment has been observed.

Report of a Case

A 42-year-old patient was treated with subcutaneous adalimumab, 40 mg every other week, for seronegative rheumatoid arthritis she had had since 1998. After 18 months of this therapy, she developed a painful hemorrhagic nodule on . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION